The proceeds will be used to expand the company’s domestic sales force and move forward with the global commercialization of Stretta therapy for gastroesophageal reflux disease.
Recent data backing the efficacy of Stretta therapy for GERD has also led to expanded insurance coverage.
More articles on gastroenterology:
5 gastroenterologists making the news
11 statistics on gastroenterology & payer relationships
3 ways gastroenterologists can demonstrate value
